<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03127358</url>
  </required_header>
  <id_info>
    <org_study_id>2016-7215</org_study_id>
    <nct_id>NCT03127358</nct_id>
  </id_info>
  <brief_title>Smartphone Based aDOT Treatment With Fixed-Dose Elbasvir and Grazoprevir in PWIDs</brief_title>
  <official_title>Smartphone Based Automated-Directly Observed Treatment Improves Adherence and SVR to Fixed-Dose Elbasvir and Grazoprevir in PWIDs: A Randomized Control Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Albert Einstein College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AiCure</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Albert Einstein College of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      People who Inject Drugs (PWIDs) constitute 60% of the approximately 5 million people in the&#xD;
      United States infected with hepatitis C virus (HCV). Successful HCV treatment leading to&#xD;
      sustained viral response (SVR) is associated with increased survival, but to date successful&#xD;
      treatment of PWIDs has been limited. Treatment of PWIDs is complex due to addiction, mental&#xD;
      illness, poverty, homelessness, lack of positive social support, poor adherence-related&#xD;
      skills, low motivation and knowledge, and poor access to and trust in the health care system.&#xD;
      At Albert Einstein College of Medicine, the investigators have developed a multidisciplinary&#xD;
      model of HCV care that integrates on-site primary care, substance abuse treatment, and&#xD;
      HCV-related care within opiate agonist treatment clinics. To optimize HCV treatment outcomes,&#xD;
      the investigators have introduced directly observed therapy (DOT). In the DOT model, one&#xD;
      daily dose of oral HCV medication is administered with methadone. However, DOT is not&#xD;
      feasible for PWIDs who are not enrolled in methadone maintenance treatment programs, and is&#xD;
      less effective for methadone-maintained PWIDs who do not attend the methadone clinics every&#xD;
      day. In addition, DOT has been used for decades both to measure and maximize adherence for&#xD;
      treatment of tuberculosis infection, but the cost and logistical complexity of administering&#xD;
      DOT for large HCV clinical programs would be prohibitive.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Automated DOT (a-DOT), a smartphone app that uses facial recognition software and advanced&#xD;
      features to detect non-ingestion, combines the accuracy of in-person DOT with the convenience&#xD;
      of real-time centralized data collection and monitoring. Adding a daily side effect diary to&#xD;
      a-DOT will further allow precise tracking of timing of both medication ingestion and side&#xD;
      effects which may be compromising adherence. Zepatier (elbasvir and grazoprevir) is a new&#xD;
      once-daily fixe-dose combination tablet which has achieved high rates of SVR ranging from 94&#xD;
      to 97 percent in genotype-1 infected patients including those with HIV/HCV coinfection and&#xD;
      renal impairment. Zepatier is administered for 12 to 16 weeks, depending on HCV genotype,&#xD;
      prior treatment history, and the presence of certain baseline NS5A polymorphisms (1a only).&#xD;
      By administering Zepatier via this innovative a-DOT platform, the investigators hypothesize&#xD;
      that PWIDs treated in real-wrold settings can be successfully treated with high rates of&#xD;
      adherence and SVR.&#xD;
&#xD;
      In this proposed 18-month trials, 75 PWIDs enrolled in opiate agonist treatment (genotypes 1a&#xD;
      and 1b) with chronic HCV will be enrolled over a 12-month period, and randomized to either&#xD;
      aDOT or treatment as usual (TAU). The investigators will recruit PWIDs from diverse community&#xD;
      settings include a syringe exchange program (NYHRE), federally-qualified health center&#xD;
      (Comprehensive Health Care Center), homeless shelter (The Living Room), and a methadone&#xD;
      maintenance treatment program (Montefiore Wellness Centers). All patients (inlcuding&#xD;
      treatment-experienced and HIVV/HCV coinfected subjects) will be treated with Zepatier-based&#xD;
      regimens as per the standard of care. Rigorous data are necessary to judge the contribution&#xD;
      of a-DOT to the success of HCV treatment in PWIDs. By performing a randomized trial of a-DOT&#xD;
      HCV therapy (Zepatier with and without ribavirin), the investigators will evaluate the&#xD;
      efficacy of a-DOT for improving HCV treatment outcomes among PWIDs.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 14, 2017</start_date>
  <completion_date type="Actual">February 6, 2019</completion_date>
  <primary_completion_date type="Actual">February 6, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HCV Treatment Adherence</measure>
    <time_frame>12 weeks</time_frame>
    <description>The amount of medication taken by each patient during the treatment period is expressed as a percentage (range 0-100%). Subjects will be classified as &quot;adherent&quot; if they receive at least 80% of the total dose of Zepatier. The numbers below denotes the mean percent of the medication the participants in each arm took.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With HCV Treatment Completion</measure>
    <time_frame>12 weeks</time_frame>
    <description>Participants will be considered to have completed treatment if they have completed at least 80% of the planned treatment course (e.g. at least 10 week of 12-week course).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Sustained Viral Response (SVR)</measure>
    <time_frame>12 weeks post treatment</time_frame>
    <description>HCV viral load undectable 12 weeks after treatment completion. Undetectable HCV viral load is defined as &lt;15 IU/ml and &quot;target not detected&quot;. IU refers to &quot;international units&quot;.One of the main outcomes looked for was the amount of patients who achieved Sustained Virologic Response (SVR) at 12 weeks post treatment, which denotes a cure of Hepatitis C.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Hepatitis C</condition>
  <condition>Medication Adherence</condition>
  <arm_group>
    <arm_group_label>AiCure App</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will use a-DOT technology called AiCure (a Smartphone App) to track ingestion of fixed-dose Elbasvir and Grazoprevir, 1 tablet, 50mg-100mg of each drug, respectively, daily for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment As Usual</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants will receive treatment for ingestion of fixed-dose Elbasvir and Grazoprevir, 1 tablet, 50mg-100mg of each drug, respectively, daily for 12 weeks without using the AiCure app.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AiCure with gamification</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sub-group of participants will use a-DOT technology called AiCure (a Smartphone app) with gaming to track ingestion of fixed-dose Elbasvir and Grazoprevir, 1 tablet, 50mg-100mg of each drug, respectively, daily for 12 weeks. The gaming feature is to test whether competition encourages engagement and helps to increase adherence to the HCV medication.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AiCure</intervention_name>
    <description>Smartphone App</description>
    <arm_group_label>AiCure App</arm_group_label>
    <other_name>a-DOT, Smartphone App</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AiCure with gamification</intervention_name>
    <description>Smartphone App with gaming.</description>
    <arm_group_label>AiCure with gamification</arm_group_label>
    <other_name>a-DOT with gamification</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  HCV-infected (HCV RNA test above the limit of quantification at baseline)&#xD;
&#xD;
          -  Genotypes/Subtypes: G1a or G1b&#xD;
&#xD;
          -  Eligible for HCV treatment per 2016 AASLD/IDSA guidelines&#xD;
&#xD;
          -  Willing to receive HCV treatment on-site at DoSA clinics&#xD;
&#xD;
          -  Health care provider decision to treat patient with Zepatier-based therapy with or&#xD;
             without ribavirin based on 2016 AASLD/IDSA guidelines&#xD;
&#xD;
          -  Using illicit drugs (either opiates, cocaine, or benzodizepenes) within the last 6&#xD;
             months&#xD;
&#xD;
          -  Age 18 or older&#xD;
&#xD;
          -  Able to provide informed consent&#xD;
&#xD;
          -  English or Spanish speaking&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known hypersensitivity (allergy) to elbasvir, grazoprevir, or ribavirin&#xD;
&#xD;
          -  Pregnant or breast-feeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julia Arnsten, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Montefiore Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Albert Einstein College of Medicine Division of Substance Abuse clinics</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 24, 2017</study_first_submitted>
  <study_first_submitted_qc>April 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 25, 2017</study_first_posted>
  <results_first_submitted>April 8, 2019</results_first_submitted>
  <results_first_submitted_qc>August 19, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">September 14, 2021</results_first_posted>
  <last_update_submitted>August 19, 2021</last_update_submitted>
  <last_update_submitted_qc>August 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Albert Einstein College of Medicine</investigator_affiliation>
    <investigator_full_name>Julia H. Arnsten</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Addiction</keyword>
  <keyword>Sustained Viral Response</keyword>
  <keyword>Adherence</keyword>
  <keyword>Adverse Effects</keyword>
  <keyword>Direct Acting Antiviral Agent</keyword>
  <keyword>Chronic Hepatitis C</keyword>
  <keyword>Resistance Development</keyword>
  <keyword>Methadone Clinic</keyword>
  <keyword>Primary Care</keyword>
  <keyword>Directly Observed Therapy</keyword>
  <keyword>Randomized Controlled Trial</keyword>
  <keyword>Resistance</keyword>
  <keyword>Reinfection</keyword>
  <keyword>Treatment Outcome</keyword>
  <keyword>Patient Navigation</keyword>
  <keyword>Multi-Site</keyword>
  <keyword>Liver Disease</keyword>
  <keyword>Intervention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 16, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/58/NCT03127358/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 23, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/58/NCT03127358/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment dates were from 11/14/17 to 7/20/18, during which 11 participants were recruited and enrolled into the study.&#xD;
Participants were recruited from a Montefiore Medical Center opioid treatment program in the Bronx. Participants were identified through chart review and provider referral, and through participant self-referral.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>AiCure App</title>
          <description>Participants will use a-DOT technology called AiCure (a Smartphone App) to track ingestion of fixed-dose Elbasvir and Grazoprevir, 1 tablet, 50mg-100mg of each drug, respectively, daily for 12 weeks.&#xD;
AiCure: Smartphone App</description>
        </group>
        <group group_id="P2">
          <title>Treatment As Usual</title>
          <description>Participants will receive treatment for ingestion of fixed-dose Elbasvir and Grazoprevir, 1 tablet, 50mg-100mg of each drug, respectively, daily for 12 weeks without using the AiCure app.</description>
        </group>
        <group group_id="P3">
          <title>AiCure With Gamification</title>
          <description>Sub-group of participants will use a-DOT technology called AiCure (a Smartphone app) with gaming to track ingestion of fixed-dose Elbasvir and Grazoprevir, 1 tablet, 50mg-100mg of each drug, respectively, daily for 12 weeks. The gaming feature is to test whether competition encourages engagement and helps to increase adherence to the HCV medication.&#xD;
AiCure with gamification: Smartphone App with gaming.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3">3/9/18:Date first participant was randomized to this arm.</participants>
                <participants group_id="P2" count="3">3/22/18: Date first participant randomized to this arm.</participants>
                <participants group_id="P3" count="5">3/14/18: Date first participant randomized to this arm..</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3">12/26/18: Date of SVR for last participant randomized to this arm.</participants>
                <participants group_id="P2" count="3">2/6/19: Date of SVR for last participant randomized to this arm.</participants>
                <participants group_id="P3" count="5">11/20/18: Date of SVR for last participant randomized to this arm.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>AiCure App</title>
          <description>Direct Observed Therapy via the AiCure app (a-DOT)</description>
        </group>
        <group group_id="B2">
          <title>Treatment As Usual</title>
          <description>Participants will receive treatment for ingestion of fixed-dose Elbasvir and Grazoprevir, 1 tablet, 50mg-100mg of each drug, respectively, daily for 12 weeks without using the AiCure app.</description>
        </group>
        <group group_id="B3">
          <title>AiCure With Gamification</title>
          <description>Sub-group of participants will use a-DOT technology called AiCure (a Smartphone app) with gaming to track ingestion of fixed-dose Elbasvir and Grazoprevir, 1 tablet, 50mg-100mg of each drug, respectively, daily for 12 weeks. The gaming feature is to test whether competition encourages engagement and helps to increase adherence to the HCV medication.&#xD;
AiCure with gamification: Smartphone App with gaming.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="5"/>
            <count group_id="B4" value="11"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53" lower_limit="43" upper_limit="59"/>
                    <measurement group_id="B2" value="60" lower_limit="40" upper_limit="71"/>
                    <measurement group_id="B3" value="58" lower_limit="50" upper_limit="66"/>
                    <measurement group_id="B4" value="57" lower_limit="43" upper_limit="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <description>Select one of the following:&#xD;
Male, Female, other (describe)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <description>count of participants who identified their ethnicity as Hispanic/Latino</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>HCV Treatment Adherence</title>
        <description>The amount of medication taken by each patient during the treatment period is expressed as a percentage (range 0-100%). Subjects will be classified as &quot;adherent&quot; if they receive at least 80% of the total dose of Zepatier. The numbers below denotes the mean percent of the medication the participants in each arm took.</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AiCure App</title>
            <description>Participants will use a-DOT technology called AiCure (a Smartphone App) to track ingestion of fixed-dose Elbasvir and Grazoprevir, 1 tablet, 50mg-100mg of each drug, respectively, daily for 12 weeks.&#xD;
AiCure: Smartphone App</description>
          </group>
          <group group_id="O2">
            <title>Treatment As Usual</title>
            <description>Participants will receive treatment for ingestion of fixed-dose Elbasvir and Grazoprevir, 1 tablet, 50mg-100mg of each drug, respectively, daily for 12 weeks without using the AiCure app.</description>
          </group>
          <group group_id="O3">
            <title>AiCure With Gamification</title>
            <description>Sub-group of participants will use a-DOT technology called AiCure (a Smartphone app) with gaming to track ingestion of fixed-dose Elbasvir and Grazoprevir, 1 tablet, 50mg-100mg of each drug, respectively, daily for 12 weeks. The gaming feature is to test whether competition encourages engagement and helps to increase adherence to the HCV medication.&#xD;
AiCure with gamification: Smartphone App with gaming.</description>
          </group>
        </group_list>
        <measure>
          <title>HCV Treatment Adherence</title>
          <description>The amount of medication taken by each patient during the treatment period is expressed as a percentage (range 0-100%). Subjects will be classified as &quot;adherent&quot; if they receive at least 80% of the total dose of Zepatier. The numbers below denotes the mean percent of the medication the participants in each arm took.</description>
          <units>percent of medication taken</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83" lower_limit="0" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="0" upper_limit="100"/>
                    <measurement group_id="O3" value="88" lower_limit="0" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With HCV Treatment Completion</title>
        <description>Participants will be considered to have completed treatment if they have completed at least 80% of the planned treatment course (e.g. at least 10 week of 12-week course).</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AiCure App</title>
            <description>Participants will use a-DOT technology called AiCure (a Smartphone App) to track ingestion of fixed-dose Elbasvir and Grazoprevir, 1 tablet, 50mg-100mg of each drug, respectively, daily for 12 weeks.&#xD;
AiCure: Smartphone App&#xD;
3 out 3 patients completed HCV treatment.</description>
          </group>
          <group group_id="O2">
            <title>Treatment As Usual</title>
            <description>Participants will receive treatment for ingestion of fixed-dose Elbasvir and Grazoprevir, 1 tablet, 50mg-100mg of each drug, respectively, daily for 12 weeks without using the AiCure app.&#xD;
3 out 3 patients completed HCV treatment.</description>
          </group>
          <group group_id="O3">
            <title>AiCure With Gamification</title>
            <description>Sub-group of participants will use a-DOT technology called AiCure (a Smartphone app) with gaming to track ingestion of fixed-dose Elbasvir and Grazoprevir, 1 tablet, 50mg-100mg of each drug, respectively, daily for 12 weeks. The gaming feature is to test whether competition encourages engagement and helps to increase adherence to the HCV medication.&#xD;
AiCure with gamification: Smartphone App with gaming.&#xD;
5 out 5 patients completed HCV treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With HCV Treatment Completion</title>
          <description>Participants will be considered to have completed treatment if they have completed at least 80% of the planned treatment course (e.g. at least 10 week of 12-week course).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Sustained Viral Response (SVR)</title>
        <description>HCV viral load undectable 12 weeks after treatment completion. Undetectable HCV viral load is defined as &lt;15 IU/ml and &quot;target not detected&quot;. IU refers to &quot;international units&quot;.One of the main outcomes looked for was the amount of patients who achieved Sustained Virologic Response (SVR) at 12 weeks post treatment, which denotes a cure of Hepatitis C.</description>
        <time_frame>12 weeks post treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AiCure App</title>
            <description>Participants will use a-DOT technology called AiCure (a Smartphone App) to track ingestion of fixed-dose Elbasvir and Grazoprevir, 1 tablet, 50mg-100mg of each drug, respectively, daily for 12 weeks.&#xD;
AiCure: Smartphone App&#xD;
3 out 3 patients achieved SVR.</description>
          </group>
          <group group_id="O2">
            <title>Treatment As Usual</title>
            <description>Participants will receive treatment for ingestion of fixed-dose Elbasvir and Grazoprevir, 1 tablet, 50mg-100mg of each drug, respectively, daily for 12 weeks without using the AiCure app.&#xD;
3 out 3 patients achieved SVR.</description>
          </group>
          <group group_id="O3">
            <title>AiCure With Gamification</title>
            <description>Sub-group of participants will use a-DOT technology called AiCure (a Smartphone app) with gaming to track ingestion of fixed-dose Elbasvir and Grazoprevir, 1 tablet, 50mg-100mg of each drug, respectively, daily for 12 weeks. The gaming feature is to test whether competition encourages engagement and helps to increase adherence to the HCV medication.&#xD;
AiCure with gamification: Smartphone App with gaming.&#xD;
5 out 5 patients achieved SVR.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Sustained Viral Response (SVR)</title>
          <description>HCV viral load undectable 12 weeks after treatment completion. Undetectable HCV viral load is defined as &lt;15 IU/ml and &quot;target not detected&quot;. IU refers to &quot;international units&quot;.One of the main outcomes looked for was the amount of patients who achieved Sustained Virologic Response (SVR) at 12 weeks post treatment, which denotes a cure of Hepatitis C.</description>
          <units>percent of patients with SVR</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The study participants were assessed from 4 months prior to enrollment, through 12 weeks of treatment, to 7 months after treatment, an average of 14 months</time_frame>
      <desc>The definition of adverse event and/or serious adverse event does not differ from the definitions on clinicaltrials.gov.</desc>
      <group_list>
        <group group_id="E1">
          <title>AiCure App</title>
          <description>Participants will use a-DOT technology called AiCure (a Smartphone App) to track ingestion of fixed-dose Elbasvir and Grazoprevir, 1 tablet, 50mg-100mg of each drug, respectively, daily for 12 weeks.&#xD;
AiCure: Smartphone App</description>
        </group>
        <group group_id="E2">
          <title>Treatment As Usual</title>
          <description>Participants will receive treatment for ingestion of fixed-dose Elbasvir and Grazoprevir, 1 tablet, 50mg-100mg of each drug, respectively, daily for 12 weeks without using the AiCure app.</description>
        </group>
        <group group_id="E3">
          <title>AiCure With Gamification</title>
          <description>Sub-group of participants will use a-DOT technology called AiCure (a Smartphone app) with gaming to track ingestion of fixed-dose Elbasvir and Grazoprevir, 1 tablet, 50mg-100mg of each drug, respectively, daily for 12 weeks. The gaming feature is to test whether competition encourages engagement and helps to increase adherence to the HCV medication.&#xD;
AiCure with gamification: Smartphone App with gaming.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination due to discontinued funding led to small numbers of subjects analyzed, and study personnel were no longer available to work on this study.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Julia Arnsten, MD</name_or_title>
      <organization>Albert Einstein College of Medicine</organization>
      <phone>718-920-6641</phone>
      <email>jarnsten@montefiore.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

